ACAB
Get informed when a big investor buys or sells
+ Follow| Market cap | $34.02 Billion |
|---|---|
| Enterprise Value | $34.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.3 |
| Beta | 0.01 |
| Outstanding Shares | 5,896,048,000 |
| P/E Ratio | -5.66 |
|---|---|
| PEG | 8.26 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6368.87 |
| Enterprise Value to Net Income | 16915 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmu...